Vascular Disrupting Agents (VDAs) represent a distinct class of antivascular cancer therapies engineered to selectively target and destroy existing tumor vasculature, leading to acute ischemia and tumor necrosis. Unlike anti-angiogenic agents that prevent new blood vessel formation, VDAs cause rapid collapse of established tumor blood vessels, offering synergistic potential when combined with...